Informações:
Falhas:
ID
28065
Descrição
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL); ODM derived from: https://clinicaltrials.gov/show/NCT00868478
Link
https://clinicaltrials.gov/show/NCT00868478
Palavras-chave
Versões (1)
- 14/12/17 14/12/17 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
14 de diciembre de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Chronic Lymphocytic Leukemia NCT00868478
Eligibility Chronic Lymphocytic Leukemia NCT00868478
- StudyEvent: Eligibility
Similar models
Eligibility Chronic Lymphocytic Leukemia NCT00868478
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Chronic Lymphocytic Leukemia
Item
b-cll confirmed according to nci criteria
boolean
C0023434 (UMLS CUI [1])
Recurrent Chronic Lymphoid Leukemia | Chronic lymphocytic leukaemia refractory Antineoplastic Therapy
Item
cll relapsed or refractory to prior antineoplastic therapy
boolean
C0854802 (UMLS CUI [1])
C0278791 (UMLS CUI [2,1])
C2346834 (UMLS CUI [2,2])
C0278791 (UMLS CUI [2,1])
C2346834 (UMLS CUI [2,2])
Signs Quantity Progressive Disease
Item
signs of progressive disease; at least one:
boolean
C0220912 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1335499 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,2])
C1335499 (UMLS CUI [1,3])
B-Symptoms
Item
b symptoms
boolean
C1706867 (UMLS CUI [1])
Lymphocyte Doubling Time
Item
lymphocyte doubling time of < 6 months
boolean
C0024264 (UMLS CUI [1,1])
C2986483 (UMLS CUI [1,2])
C2986483 (UMLS CUI [1,2])
Lymphadenopathy Symptomatic | Splenomegaly Symptomatic
Item
symptomatic lymphadenopathy or splenomegaly
boolean
C0497156 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0038002 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
C0231220 (UMLS CUI [1,2])
C0038002 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
Cytopenia Due to Bone marrow failure
Item
cytopenias due to bone marrow failure)
boolean
C0010828 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C1855710 (UMLS CUI [1,3])
C0678226 (UMLS CUI [1,2])
C1855710 (UMLS CUI [1,3])
Age
Item
age > 18 years, and less then 80
boolean
C0001779 (UMLS CUI [1])
Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Serum total bilirubin measurement | Creatinine measurement, serum
Item
serum alat, asat, bilirubin, creatinine < 2x upper limit of normal
boolean
C0201836 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
C0201899 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
Life Expectancy
Item
life expectancy > 6 months
boolean
C0023671 (UMLS CUI [1])
Informed Consent
Item
patient's written informed consent
boolean
C0021430 (UMLS CUI [1])
Bacterial Infections | Virus Diseases
Item
active bacterial or viral infection
boolean
C0004623 (UMLS CUI [1])
C0042769 (UMLS CUI [2])
C0042769 (UMLS CUI [2])
Hypersensitivity Humanized Monoclonal Antibodies
Item
hypersensitivity to humanized monoclonal antibodies
boolean
C0020517 (UMLS CUI [1,1])
C2985546 (UMLS CUI [1,2])
C2985546 (UMLS CUI [1,2])
Antineoplastic Therapy CLL | Antineoplastic Therapy Malignant Neoplasms
Item
concurrent antineoplastic treatment for cll or other malignant disease
boolean
C2346834 (UMLS CUI [1,1])
C0023434 (UMLS CUI [1,2])
C2346834 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
C0023434 (UMLS CUI [1,2])
C2346834 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
Absolute neutrophil count
Item
absolute neutrophil count < 1.5 k/
boolean
C0948762 (UMLS CUI [1])